Life Technologies Corporation
) launched the Oncomine Next Gen Sequencing Power Tools. This
innovative offering from the company is an analytical tool to
enable in-depth analysis of next generation sequencing (NGS) data
for oncology research.
HAEMONETICS CP (HAE): Free Stock Analysis
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
MYRIAD GENETICS (MYGN): Free Stock Analysis
THERMO FISHER (TMO): Free Stock Analysis
To read this article on Zacks.com click here.
The NGS data is sourced from the data from The Cancer Genome
Atlas. NGS is capable of providing insights into the factors
inducing cancer. To date, over 4,500 paired tumor and samples
have been analyzed.
The Oncomine NGS Power Tools is an accretive addition to Life's
Power Tools line of products. Moreover, this innovative offering
from the company reflects its ability to cater to the broader
needs of the cancer research space.
The Oncomine portfolio was included in the company's profile
following the takeover of Compendia Bioscience in Oct 2012.
Earlier this year, in April, Life introduced its Oncomine Gene
Browser and Ion Reporter Oncomine Workflow. The Oncomine Gene
Browser is targeting the academic and smaller biotech market.
About Oncomine NGS Power Tools
Life's latest portfolio addition comprises an array of software
tools that will allow researchers to assess novel predicted
driver mutations and gene fusions for all types of cancer. The
Oncomine NGS Power Tools will allow cancer researchers access to
extensive recent data.
According to the company, investigators using the NGS Power Tools
identified FGFR gene fusions across different cancer types. The
nine distinguished tumor types uncovered by scientists at Life
are lung squamous cell cancer, bladder cancer, thyroid cancer,
oral cancer, glioblastoma, and head and neck squamous cell
Following the disclosure of its acquisition by
Thermo Fisher Scientific Inc
), Life sharpened focus on its product platform. We believe that
the buyout will leverage Life's attractive revenue profile. The
acquisition is expected to close in early 2014.
Given Life's expansive line of consumables for genomic, and
molecular and cell biology, the takeover will complement Thermo
Fisher's market-leading portfolio of analytical technologies and
However, with the current stock price reflecting the potential
upsides, Life carries a Zacks Rank #4 (Sell). While the upsides
are already built into Life's shares, we are more positive about
other medical stocks such as
Myriad Genetics Inc
). These stocks carry a favorable Zacks Rank #1 (Strong Buy).